Journal
CLINICAL CANCER RESEARCH
Volume 19, Issue 22, Pages 6064-6066Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-13-2461
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA174777] Funding Source: Medline
Ask authors/readers for more resources
E7107 is a derivative of the pladienolide family of natural product spliceosome inhibitors, which targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b. The results of a first-in-human trial with E7107 have been reported, representing an important translational step toward the goal of modulating RNA splicing for cancer therapy. (C) 2013 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available